Tesamorelin results get misread for a reason written into the label: the fat this molecule removes is fat a bathroom scale does not weigh.<\/p>\n
In the trials that made it a drug, tesamorelin results meant roughly 15% less visceral fat over 26 weeks, a measurable cut in liver fat, and no meaningful change in body weight. The label says so in plain words: EGRIFTA SV is “not indicated for weight loss management as it has a weight neutral effect,” according to the prescribing information published on DailyMed on July 31, 2026.<\/p>\n
Whether “tesamorelin works” depends entirely on what you were promised. If someone sold it to you as a weight-loss drug, the answer is no, and it was no from the start. If the goal was the fat packed around the organs, there is real trial evidence, and it is unusually specific.<\/p>\n
Human fat is not one tissue. Subcutaneous fat sits under the skin and is what a caliper, a tape measure and a mirror all report. Visceral adipose tissue wraps the organs inside the abdominal wall. You cannot pinch it. You can barely feel it. It is measured by CT or MRI scan, and it is the fat most tightly linked to metabolic trouble.<\/p>\n
Tesamorelin is a growth hormone-releasing factor analog. It tells the pituitary to release the body’s own growth hormone rather than delivering growth hormone itself. The trials measured the tissue mechanically, in square centimeters on a scan, not in pounds on a floor tile.<\/p>\n
The clearance for this molecule is narrow and worth saying out loud. EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, not for general obesity or cosmetic fat reduction. The same label states that long-term cardiovascular safety has not been established.<\/p>\n
The two pivotal phase 3 trials were pooled and published by Falutz and colleagues in the Journal of Clinical Endocrinology and Metabolism<\/em> in 2010. Eight hundred and six antiretroviral-treated adults with excess abdominal fat were randomized two to one to tesamorelin or placebo. At week 26, visceral fat fell by 24 cm\u00b2 on tesamorelin and rose by 2 cm\u00b2 on placebo, a treatment effect of \u221215.4%. Abdominal subcutaneous fat did not budge: \u22122 versus 2 cm\u00b2, a treatment effect of \u22120.6%, not statistically significant.<\/p>\n A separate 404-patient trial, published by Falutz and colleagues in the Journal of Acquired Immune Deficiency Syndromes<\/em> in 2010, found visceral fat down 10.9% (\u221221 cm\u00b2) against \u22120.6% on placebo at six months, with trunk fat, waist circumference and waist-to-hip ratio all improving and limb fat unchanged.<\/p>\n Visceral fat sits next to the liver, and the liver was the next question. Stanley and colleagues ran a 50-patient double-blind trial at Massachusetts General Hospital, published in JAMA<\/em> in 2014. Over six months, visceral fat treatment effect was \u221242 cm\u00b2 (95% CI, \u221271 to \u221214; P = .005) and liver fat fell by a net \u22122.9% on magnetic resonance spectroscopy (P = .003). That was a small mechanistic study, and it pointed somewhere.<\/p>\n The follow-up was definitive enough to matter. Stanley and colleagues published a 61-patient, 12-month, double-blind, multicenter trial in Lancet HIV<\/em> in 2019, enrolling people with HIV and a hepatic fat fraction of 5% or more. Tesamorelin beat placebo on the primary endpoint: an absolute hepatic fat fraction reduction of \u22124.1 percentage points (95% CI, \u22127.6 to \u22120.7; P = .018), which the authors described as a relative reduction of about 37%.<\/p>\n In 2024, Russo and colleagues re-analyzed 38 participants from that trial who were taking integrase inhibitors, the modern backbone of HIV therapy, and published in AIDS<\/em>. Visceral fat fell 25 cm\u00b2 against a 14 cm\u00b2 rise on placebo (P = .001), hepatic fat fell 4.2% against 0.5% (P = .01). The phase 3 trials were run before those drugs existed, so this was the first dedicated look at the population a clinic would see today.<\/p>\n Badran and colleagues pooled five randomized trials in Obesity Research and Clinical Practice<\/em> in 2026. Visceral fat: mean difference \u221227.71 cm\u00b2 (95% CI, \u221238.37 to \u221217.06). Trunk fat: \u22121.18 kg. Waist circumference: \u22121.61 cm. Hepatic fat: \u22124.28%. Lean body mass: +1.42 kg.<\/p>\n There was no significant reduction in subcutaneous fat and no significant reduction in BMI.<\/p>\n A second 2026 review, by Ditta and colleagues in the Journal of the International Association of Providers of AIDS Care<\/em>, combined four trials covering 909 people and reached the same place: less abdominal fat, smaller waist, less trunk fat, slightly more lean mass, modest cholesterol improvement, and side effects to weigh.<\/p>\n If a marketing page shows you a tesamorelin before-and-after and the only before-and-after is a body photo, the photo is not the result the studies measured.<\/p>\n All of the efficacy trials above enrolled adults with HIV and excess abdominal fat. That is the population the evidence describes, and there is no large trial of tesamorelin in people without HIV. One 12-week safety study in 53 patients with type 2 diabetes, published by Clemmons and colleagues in PLoS One<\/em> in 2017, found no change in insulin response or glycemic control, which is reassuring about short-term glucose handling and is not evidence of fat loss in that population.<\/p>\n The label also carries the costs. Tesamorelin raises IGF-1, and the effects of prolonged elevation are unknown, so the label directs monitoring of IGF-1 during therapy. Fluid retention, joint pain, peripheral edema and carpal tunnel syndrome appear among the most commonly reported adverse reactions at rates above 5%. Glucose intolerance or diabetes may develop, so glucose is evaluated before and during treatment. Active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy and known hypersensitivity are contraindications. The EGRIFTA SV label directs 1.4 mg subcutaneously once daily for that formulation. That figure is the label’s, not a plan. Dosing belongs to the prescriber holding the labs.<\/p>\n EGRIFTA is an FDA-approved prescription product for HIV-associated lipodystrophy. A compounded tesamorelin vial is not that product, is not FDA-approved, and does not carry that label’s manufacturing, potency or sterility guarantees. Tesamorelin does not appear on the FDA’s list of bulk drug substances that may present significant safety risks as of October 28, 2026, but absence from a warning list has never been approval.<\/p>\n Ask what was measured. If the answer is a number on a scale or a photograph, the number is about a different tissue than the one the trials moved. If the answer is visceral fat on CT or MRI, ask in whom, because the evidence is in adults with HIV and lipodystrophy.<\/p>\n Ask whether IGF-1 and glucose were checked before and during treatment. A clinic selling this molecule without those labs is selling a growth hormone secretagogue to someone it has not measured.<\/p>\n And ask what happens at month six. The label asks prescribers to reconsider continuing in patients who have not had a reduction in visceral adipose tissue. That is a stop rule, written by the manufacturer. If you are trying to work out which clinics will run those checks, our clinic directory<\/a> lists clinics by city; check each license yourself. The compounds hub<\/a> explains what each peptide is before anyone injects it.<\/p>\n No. The FDA label for EGRIFTA SV states it is not indicated for weight loss management and has a weight-neutral effect, and the 2026 five-trial meta-analysis found no significant reduction in BMI.<\/p>\n In the pooled phase 3 trials the treatment effect was \u221215.4% visceral fat at 26 weeks. The 2026 meta-analysis of five trials reported a mean difference of \u221227.71 cm\u00b2.<\/p>\n The pivotal trials measured the primary endpoint at 26 weeks, and the liver fat trial ran 12 months. No one has published a reliable early response window, and a scale reading at week four tells you nothing about visceral fat.<\/p>\n Yes, in people with HIV. The 2019 Lancet HIV trial found an absolute hepatic fat fraction reduction of 4.1 percentage points against placebo at 12 months, about 37% relative, in people who started with at least 5% liver fat.<\/p>\n No. Egrifta is an FDA-approved product for HIV-associated lipodystrophy. A compounded vial is not FDA-approved, is not interchangeable by default, and does not carry the approved label’s monitoring requirements, which is precisely the part that matters.<\/p>\n The efficacy data comes from adults with HIV and excess abdominal fat. There is no large trial in people without HIV, so any claim about results in that population is extrapolation rather than evidence.<\/p>\n Elevated IGF-1 with unknown long-term effects, fluid retention, joint and muscle pain, carpal tunnel syndrome, glucose intolerance or new diabetes, injection site reactions, and an increased risk of neoplasms in a population already at higher baseline risk. The label directs IGF-1 and glucose monitoring.<\/p>\n This page is educational information, not medical advice, a diagnosis, or a treatment recommendation. It does not recommend any peptide, medication, pharmacy, clinic, or treatment plan, and it makes no claim that any unapproved substance is safe or effective. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before they are marketed. Doses vary, and the decision about a prescription belongs to a licensed clinician who knows your history. Talk to your prescriber about your own situation, and see our full medical disclaimer<\/a>.<\/p>\nLiver Fat: The Finding the Label Did Not Promise<\/h2>\n
The 2026 Meta-Analysis: Five Trials, and the Number That Is Missing<\/h2>\n
What Tesamorelin Results Do Not Include<\/h2>\n
How to Read a Tesamorelin Result Someone Shows You<\/h2>\n
Frequently asked questions<\/h2>\n
Does tesamorelin work for weight loss?<\/h3>\n
How much visceral fat does tesamorelin remove?<\/h3>\n
How long before tesamorelin results show up?<\/h3>\n
Does tesamorelin reduce liver fat?<\/h3>\n
Is compounded tesamorelin the same as Egrifta?<\/h3>\n
Can you take tesamorelin without HIV?<\/h3>\n
What are the main risks of tesamorelin?<\/h3>\n
Sources<\/h2>\n
\n